Since 2012, other biomarker-guided therapies emerged for the treatment of cancer in digestive organs (especially relevant for colorectal cancer with EGFR and KRAS testing, and gastric cancer with HER2), skin cancer (melanoma with BRAF and NRAS), and cancer in the respiratory system (lung cancer with EGFR). The gene discussed is KRAS; the disease is colorectal cancer.